Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Conferences
Guide to authors
Online submissionOnline submission
Permissions
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
naturereprints
About this site
For librarians
 
NPG Resources
Bioentrepreneur
Nature Reviews Drug Discovery
Nature
Nature Medicine
Nature Genetics
Nature Reviews Genetics
Nature Methods
Nature Chemical Biology
news@nature.com
Clinical Pharmacology & Therapeutics
Nature Conferences
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Technical Report
Nature Biotechnology  19, 1173 - 1176 (2001)
doi:10.1038/nbt1201-1173

A peptide carrier for the delivery of biologically active proteins into mammalian cells

May C. Morris, Julien Depollier, Jean Mery, Frederic Heitz & Gilles Divita

Centre de Recherches de Biochimie Macromoléculaire, UPR-1086 CNRS, 1919 Route de Mende, 34293 Montpellier, Cedex 5, France.

Correspondence should be addressed to Gilles Divita divita@crbm.cnrs-mop.fr
The development of peptide drugs and therapeutic proteins is limited by the poor permeability and the selectivity of the cell membrane. There is a growing effort to circumvent these problems by designing strategies to deliver full-length proteins into a large number of cells1, 2, 3. A series of small protein domains, termed protein transduction domains (PTDs), have been shown to cross biological membranes efficiently and independently of transporters or specific receptors, and to promote the delivery of peptides and proteins into cells. TAT protein from human immunodeficiency virus (HIV-1) is able to deliver biologically active proteins in vivo and has been shown to be of considerable interest for protein therapeutics4, 5, 6, 7, 8, 9. Similarly, the third alpha-helix of Antennapedia homeodomain10, 11, 12, and VP22 protein from herpes simplex virus13, 14 promote the delivery of covalently linked peptides or proteins into cells. However, these PTD vectors display a certain number of limitations in that they all require crosslinking to the target peptide or protein. Moreover, protein transduction using PTD−TAT fusion protein systems may require denaturation of the protein before delivery to increase the accessibility of the TAT−PTD domain. This requirement introduces an additional delay between the time of delivery and intracellular activation of the protein1. In this report, we propose a new strategy for protein delivery based on a short amphipathic peptide carrier, Pep-1. This peptide carrier is able to efficiently deliver a variety of peptides and proteins into several cell lines in a fully biologically active form, without the need for prior chemical covalent coupling or denaturation steps. In addition, this peptide carrier presents several advantages for protein therapy, including stability in physiological buffer, lack of toxicity, and lack of sensitivity to serum. Pep-1 technology should be extremely useful for targeting specific protein−protein interactions in living cells and for screening novel therapeutic proteins.

MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated

RESEARCH
Combination of a new generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycle progression
Gene Therapy Research Article (01 May 2004)

 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

Open Innovation Challenges

  • Corrosion Inhibitor

    • Deadline: Aug 19 2009
    • Reward: $10,000 USD

    The Seeker is looking for inhibitors of corrosion. This Challenge requires only a written descripti...

  • Protect Enzyme from In Planta Degradation

    • Deadline: Jul 15 2009
    • Reward: $20,000 USD

    A proposal for stable expression of an enzyme in corn seed is desired.

naturejobs

Figures & Tables
Export citation
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Biotechnology
ISSN: 1087-0156
EISSN: 1546-1696
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | Conferences | For authors | Online submission | Permissions | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | naturereprints | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2001 Nature Publishing Group | Privacy policy